• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Tevogen Inc. - Warrant (NQ:TVGNW)

    0.0607 -0.0088 (-12.66%)
    Delayed Quote Updated: 1:49 PM EDT, Oct 1, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Press Releases about Tevogen Inc. - Warrant

    < Previous 1 2 3 4 5 6 Next >
    News headline image
    Tevogen Regains Compliance with Nasdaq Global Market Continued Listing Requirements
    Both previously disclosed Nasdaq compliance matters are now closed 
    From Tevogen Inc.
    Via GlobeNewswire
    News headline image
    Tevogen Bio Holdings Inc. Becomes Tevogen Inc.
    From Tevogen Bio Inc
    Via GlobeNewswire
    News headline image
    Tevogen Bio Announces 2026 Annual Meeting of Stockholders
    From Tevogen Bio Inc
    Via GlobeNewswire
    News headline image
    Tevogen Announces Formation of a Healthcare Services Initiative
    From Tevogen Bio Inc
    Via GlobeNewswire
    News headline image
    Tevogen Advances Strategic Acquisition Initiatives with Potential to Support Approximately $100 Million in Combined Annual Revenue
    From Tevogen Bio Inc
    Via GlobeNewswire
    News headline image
    Tevogen Signs Letter of Intent to Evaluate Potential Acquisition of a Management Services Organization
    From Tevogen Bio Inc
    Via GlobeNewswire
    News headline image
    Letter to Shareholders from CEO Dr. Ryan Saadi
    From Tevogen Bio Inc
    Via GlobeNewswire
    News headline image
    Tevogen Announces $3 Million Private Investment at $8 Per Share, a 14% Premium from Latest Market Close
    From Tevogen Bio Inc
    Via GlobeNewswire
    News headline image
    Tevogen.AI Nears Completion of PredicTcell™ Training; Initiates Commercial Readiness and Debuts Internal Application Portal
    From Tevogen Bio Inc
    Via GlobeNewswire
    News headline image
    Tevogen Advances Strategic CRO Evaluation to Expand Clinical Research Delivery Capabilities and Drive Revenue Growth
    From Tevogen Bio Inc
    Via GlobeNewswire
    News headline image
    Tevogen Regains Compliance with Nasdaq Minimum Bid Price Requirement
    From Tevogen Bio Inc
    Via GlobeNewswire
    News headline image
    Tevogen CIO and Head of Tevogen.AI Mittul Mehta to Speak at Microsoft Fabric Community Conference (FabCon 2026)
    From Tevogen Bio Inc
    Via GlobeNewswire
    News headline image
    Tevogen Reaffirms Capital Discipline as Lead Investor Maintains Holdings and Company Limits Share Utilization
    From Tevogen Bio Inc
    Via GlobeNewswire
    News headline image
    Tevogen.AI Reports Advancements in PredicTcell™ Beta, Demonstrates Improved Precision Metrics and Expands Proprietary AI Infrastructure
    From Tevogen Bio Inc
    Via GlobeNewswire
    News headline image
    Tevogen CEO Dr. Ryan Saadi Reaffirms Clinical Commitment During International Long COVID Awareness Month; Highlights Synergies of New Leadership Team and Digital Care Platform
    From Tevogen Bio Inc
    Via GlobeNewswire
    News headline image
    Tevogen Names Leadership Team to Execute Diversified Growth Strategy
    From Tevogen Bio Inc
    Via GlobeNewswire
    News headline image
    Letter to Shareholders from CEO Dr. Ryan Saadi
    From Tevogen Bio Inc
    Via GlobeNewswire
    News headline image
    Tevogen Advances Generics Strategy, Signs Letter of Intent to Evaluate Potential Acquisition of Apozeal Pharmaceutical
    From Tevogen Bio Inc
    Via GlobeNewswire
    News headline image
    Tevogen Announces Reverse Stock Split
    From Tevogen Bio Inc
    Via GlobeNewswire
    News headline image
    Tevogen Signs Letter of Intent to Evaluate Potential Acquisition of a Contract Research Organization
    From Tevogen Bio Inc
    Via GlobeNewswire
    News headline image
    UPDATE - Tevogen Signs Letter of Intent to Evaluate Potential Acquisition of Sciometrix and its Digital Care Management Platform Clinicus
    From Tevogen Bio Inc
    Via GlobeNewswire
    News headline image
    Tevogen Signs Letter of Intent to Evaluate Potential Acquisition of Sciometrix and its Digital Care Management Platform Clinicus
    From Tevogen Bio Inc
    Via GlobeNewswire
    News headline image
    Tevogen Board to Evaluate Potential One-Time Special Cash Dividend to Shareholders
    From Tevogen Bio Inc
    Via GlobeNewswire
    News headline image
    Tevogen to Align Long-Term Stock-Based Incentive Program With Company Milestones, Including Revenue
    From Tevogen Bio Inc
    Via GlobeNewswire
    News headline image
    Tevogen Demonstrates Platform Scalability and Multi-Indication T Cell Pipeline Expansion in 2025
    From Tevogen Bio Inc
    Via GlobeNewswire
    News headline image
    Tevogen CEO Donates Shares to Support Education for Underprivileged Children
    From Tevogen Bio Inc
    Via GlobeNewswire
    News headline image
    Tevogen CEO Donates Personal Shares to Support Local Fire Department
    From Tevogen Bio Inc
    Via GlobeNewswire
    News headline image
    Tevogen CEO Supports Local Law Enforcement with Personal Contribution of 230,000 Company’s Shares of Common Stock
    From Tevogen Bio Inc
    Via GlobeNewswire
    News headline image
    Tevogen Celebrates Board Member Dr. Curtis Patton, Honored by Yale University for Distinguished Career and Lasting Contributions to Medical Education and Equity in Medicine
    From Tevogen Bio Inc
    Via GlobeNewswire
    News headline image
    Tevogen Recognized on 2025 NJBIZ Power List Amid Growth and Multi-Billion-Dollar Revenue Outlook
    From Tevogen Bio Inc
    Via GlobeNewswire
    < Previous 1 2 3 4 5 6 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.